Why MA Appeals Follow a Federal Structure, Not a Payer-Specific One
Unlike commercial plan appeals, which each carrier designs largely on its own, Medicare Advantage appeals follow a structure set at the federal level and applied consistently across every MA carrier — Aetna, Humana, UHC, and others all administer the same fundamental appeal ladder for their MA plans, even though the plans themselves compete commercially.
The Five Levels at a Glance
The general structure moves from an initial reconsideration by the plan itself, to review by an independent entity if the plan upholds its denial, to further administrative review levels for cases that remain unresolved and meet applicable dollar thresholds, with the potential for judicial review at the furthest end for the highest-dollar, most contested disputes. Each level has procedural requirements and deadlines set by federal rule, and billing teams should confirm current specifics against CMS guidance rather than relying on a fixed description, since procedural details are periodically updated.
Why the Independent Review Step Matters Most for Billing Teams
The second level — independent review by an entity outside the plan — is often the most consequential step in practice, because it removes the original denying plan from the decision entirely. Appeals that reach this level benefit from being built with that independent reviewer in mind from the start: clear, self-contained clinical documentation that doesn't assume the reviewer has any prior context about the case.
What This Means for Multi-Specialty Groups Billing Multiple MA Carriers
Because the appeal ladder itself is consistent across MA carriers, a group that builds strong internal process for one MA carrier's appeals can largely reuse that process for another — a genuine efficiency advantage over commercial appeals, where each payer's process has to be learned and tracked separately.
ResolveRCM structures Medicare Advantage appeals to hold up at every level of the federal appeal ladder, not just the first. Learn more. |